Figure 3
Monitoring patients’ individual therapy response by plotting their MR course over 18 months against the continuous references of the optimal responders. (a) a male patient (4 years old at diagnosis, e14a2 transcript) with uninterrupted imatinib therapy (b) a female patient (15 years old at diagnosis, e13a2 + e14a2 transcript) with uninterrupted imatinib therapy, and (c) a male patient (13 years old at diagnosis, e13a2 transcript) with imatinib therapy for 131 days and a subsequent TKI switch to dasatinib. Black circles represent measurements under the imatinib treatment; grey squares represent measurements under the dasatinib treatment. Triangles indicate non-detectable BCR::ABL1 transcript levels.
